Badanie kliniczne nad abrocitinibem u pacjentów z umiarkowanym do ciężkiego przewlekłym wypryskiem rąk opornym na terapię kortykosteroidami

Chronic hand eczema is a skin condition that causes redness, itching, and sometimes blisters on the hands. It can be difficult to treat, especially when it doesn't respond well to common treatments like corticosteroids. This study is looking at a new treatment option for people with moderate to severe chronic hand eczema that hasn't improved with corticosteroid therapy. The treatment being tested is called abrocitinib, which is a type of medication known as a Janus kinase (JAK)1 inhibitor. This medication is taken in the form of film-coated tablets.

The purpose of the study is to see how well abrocitinib works in reducing the symptoms of chronic hand eczema and to check its safety and how well it is tolerated by patients. Participants in the study will be randomly assigned to receive either the abrocitinib tablets or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for several weeks, during which participants will take the tablets and have regular check-ups to monitor their condition and any side effects.

Throughout the study, doctors will assess changes in the severity of the eczema and any improvements in the skin condition. The study aims to provide more information about the effectiveness of abrocitinib as a treatment for chronic hand eczema, offering hope for those who have not found relief with other treatments.